Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CompoSIT-R: Sitagliptin vs Dapagliflozin in T2DM with Mild Renal Impairment
NCT02532855Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Oct 2015; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02532855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532855.